Skip to main content
Top
Published in: Pituitary 2/2019

01-04-2019

Clinical score system in the treatment of Cushing’s disease: failure to identify discriminative variables from the German Cushing’s Registry

Authors: Mareike R. Stieg, Matthias K. Auer, Christina Berr, Julia Fazel, Martin Reincke, Stephanie Zopp, Alexander Yassouridis, Günter K. Stalla

Published in: Pituitary | Issue 2/2019

Login to get access

Abstract

Purpose

To develop a multidimensional and integrated clinical scoring instrument, that encompasses, summarizes and weights appropriately the desired clinical benefits of a treatment for Cushing’s disease (CD).

Methods

A panel of 42 variables potentially relevant to the clinical course of CD was predefined by endocrinology experts taking into account relevant literature. Variables as well as biochemical disease activity assessed as urinary free cortisol (UFC) levels were evaluated at baseline and at least after 12 months in patients treated between 2012 and 2016 in two Munich-based academic centres of the German Cushing’s Registry. The primary endpoint was the identification of variables whose changes from baseline to follow-up visit(s) could characterize well biochemical cured from not cured patients after 12 months.

Results

Ninety nine patients with at least two consecutive visits were enrolled. Biochemical data were available for 138 visit-pairs among which UFC was not controlled in 48 (34.8%) and controlled in 90 (65.2%) first visits. In 41 (29.7%) consecutive visits (visit-pairs) changes in biochemical activity categories was observed between visits; concretely: in 17 (12.3%) consecutive visits changing from previously controlled to not controlled, and in 24 (17.4%) from uncontrolled to controlled biochemical activity. Multivariate statistical analyses (especially analyses of variance) based on data of the 138 visit-pairs were performed in order to proof possible effects of biochemical activity on clinical benefits. However, in none of the considered 42 variables corresponding to quality of life-dimensions, laboratory, anthropometric, musculo-skeletal or other clinical areas any statistically significant differences between different categories of biochemical activity were observed.

Conclusion

It was not possible to provide clinical key parameters in our population of patients with CD discriminating biochemical cured from non-cured patients and to construct a clinical scoring system reflecting clinical treatment benefits.
Literature
1.
go back to reference Boscaro M, Barzon L, Fallo F, Sonino N (2001) Cushing’s syndrome. Lancet 357(9258):783–791CrossRef Boscaro M, Barzon L, Fallo F, Sonino N (2001) Cushing’s syndrome. Lancet 357(9258):783–791CrossRef
2.
go back to reference Berr CM, Ritzel K, Osswald A, Schopohl J, Beuschlein F, Reincke M (2014) Time from symptoms to diagnosis in Cushing’s syndrome: results of the German Cushing Registry in Munich. Exp Clin Endocrinol Diabetes 122:LB18CrossRef Berr CM, Ritzel K, Osswald A, Schopohl J, Beuschlein F, Reincke M (2014) Time from symptoms to diagnosis in Cushing’s syndrome: results of the German Cushing Registry in Munich. Exp Clin Endocrinol Diabetes 122:LB18CrossRef
3.
go back to reference Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM (2011) The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165(3):383–392CrossRef Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM (2011) The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165(3):383–392CrossRef
4.
go back to reference Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96(3):632–642CrossRef Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96(3):632–642CrossRef
5.
go back to reference Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed
6.
go back to reference Stewart PM, Sherlock M (2012) Mortality and pituitary disease. Ann Endocrinol (Paris) 73(2):81–82CrossRef Stewart PM, Sherlock M (2012) Mortality and pituitary disease. Ann Endocrinol (Paris) 73(2):81–82CrossRef
7.
go back to reference Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M, Tsagarakis S, Grossman AB, Wass JA, Karavitaki N (2013) Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 169(5):715–723CrossRef Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M, Tsagarakis S, Grossman AB, Wass JA, Karavitaki N (2013) Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 169(5):715–723CrossRef
8.
go back to reference Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jorgensen JO (2012) Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med 23(3):278–282CrossRef Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jorgensen JO (2012) Mortality in Cushing’s syndrome: a systematic review and meta-analysis. Eur J Intern Med 23(3):278–282CrossRef
9.
go back to reference Sharma ST, Nieman LK, Feelders RA (2015) Comorbidities in Cushing’s disease. Pituitary 18(2):188–194CrossRef Sharma ST, Nieman LK, Feelders RA (2015) Comorbidities in Cushing’s disease. Pituitary 18(2):188–194CrossRef
10.
go back to reference Pivonello R, Faggiano A, Lombardi G, Colao A (2005) The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin North Am 34(2):327–339 viiiCrossRef Pivonello R, Faggiano A, Lombardi G, Colao A (2005) The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin North Am 34(2):327–339 viiiCrossRef
11.
go back to reference Ferrau F, Korbonits M (2015) Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 173(4):M133–M157CrossRef Ferrau F, Korbonits M (2015) Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 173(4):M133–M157CrossRef
12.
go back to reference Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311–326CrossRef Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311–326CrossRef
13.
go back to reference van Haalen FM, Broersen LH, Jorgensen JO, Pereira AM, Dekkers OM (2015) Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis. Eur J Endocrinol 172(4):R143–R149CrossRef van Haalen FM, Broersen LH, Jorgensen JO, Pereira AM, Dekkers OM (2015) Management of endocrine disease: mortality remains increased in Cushing’s disease despite biochemical remission: a systematic review and meta-analysis. Eur J Endocrinol 172(4):R143–R149CrossRef
14.
go back to reference Sonino N, Fava GA (1998) Psychosomatic aspects of Cushing’s disease. Psychother Psychosom 67(3):140–146CrossRef Sonino N, Fava GA (1998) Psychosomatic aspects of Cushing’s disease. Psychother Psychosom 67(3):140–146CrossRef
15.
go back to reference Santos A, Resmini E, Martinez MA, Marti C, Ybarra J, Webb SM (2009) Quality of life in patients with pituitary tumors. Curr Opin Endocrinol Diabetes Obes 16(4):299–303CrossRef Santos A, Resmini E, Martinez MA, Marti C, Ybarra J, Webb SM (2009) Quality of life in patients with pituitary tumors. Curr Opin Endocrinol Diabetes Obes 16(4):299–303CrossRef
16.
go back to reference Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW, Glusman JE (2008) Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 158(5):623–630CrossRef Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW, Glusman JE (2008) Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 158(5):623–630CrossRef
17.
go back to reference Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing’s disease. Endocr Rev 36(4):385–486CrossRef Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing’s disease. Endocr Rev 36(4):385–486CrossRef
18.
go back to reference Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C (2014) Global clinical response in Cushing’s syndrome patients treated with mifepristone. Clin Endocrinol (Oxf) 80(4):562–569CrossRef Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C (2014) Global clinical response in Cushing’s syndrome patients treated with mifepristone. Clin Endocrinol (Oxf) 80(4):562–569CrossRef
19.
go back to reference Sundaram NK, Carluccio A, Geer EB (2014) Characterization of persistent and recurrent Cushing’s disease. Pituitary 17(4):381–391CrossRef Sundaram NK, Carluccio A, Geer EB (2014) Characterization of persistent and recurrent Cushing’s disease. Pituitary 17(4):381–391CrossRef
20.
go back to reference McCance DR, Besser M, Atkinson AB (1996) Assessment of cure after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol (Oxf) 44(1):1–6CrossRef McCance DR, Besser M, Atkinson AB (1996) Assessment of cure after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol (Oxf) 44(1):1–6CrossRef
21.
go back to reference Nugent CA, Warner HR, Dunn JT, Tyler FH (1964) Probability theory in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 24:621–627CrossRef Nugent CA, Warner HR, Dunn JT, Tyler FH (1964) Probability theory in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 24:621–627CrossRef
22.
go back to reference Castinetti F, Morange I, Conte-Devolx B, Brue T (2012) Cushing’s disease. Orphanet J Rare Dis 7:41CrossRef Castinetti F, Morange I, Conte-Devolx B, Brue T (2012) Cushing’s disease. Orphanet J Rare Dis 7:41CrossRef
23.
go back to reference Nieman LK (2015) Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol 173(4):M33–M38CrossRef Nieman LK (2015) Cushing’s syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol 173(4):M33–M38CrossRef
24.
go back to reference Pereira AM, Tiemensma J, Romijn JA (2010) Neuropsychiatric disorders in Cushing’s syndrome. Neuroendocrinology 92(S1):65–70CrossRef Pereira AM, Tiemensma J, Romijn JA (2010) Neuropsychiatric disorders in Cushing’s syndrome. Neuroendocrinology 92(S1):65–70CrossRef
25.
go back to reference Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S, Group SI (2016) SAGIT(R): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. Pituitary 19(1):39–49CrossRef Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S, Group SI (2016) SAGIT(R): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. Pituitary 19(1):39–49CrossRef
26.
go back to reference van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, Burman P, Clemmons D, Ghigo E, Jørgensen JOL, Luger A, van der Lans-Bussemaker J, Webb SM, Strasburger CJ (2017) Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary 20(6):692–701CrossRef van der Lely AJ, Gomez R, Pleil A, Badia X, Brue T, Buchfelder M, Burman P, Clemmons D, Ghigo E, Jørgensen JOL, Luger A, van der Lans-Bussemaker J, Webb SM, Strasburger CJ (2017) Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary 20(6):692–701CrossRef
Metadata
Title
Clinical score system in the treatment of Cushing’s disease: failure to identify discriminative variables from the German Cushing’s Registry
Authors
Mareike R. Stieg
Matthias K. Auer
Christina Berr
Julia Fazel
Martin Reincke
Stephanie Zopp
Alexander Yassouridis
Günter K. Stalla
Publication date
01-04-2019
Publisher
Springer US
Published in
Pituitary / Issue 2/2019
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-019-00942-2

Other articles of this Issue 2/2019

Pituitary 2/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.